SCHEMBL1359797

SCHEMBL1359797

CC(C)(C)c1cc(-c2ccc[nH]c2=O)cc2c(C(=O)N3CCCC(O)C3)coc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 1/20 0.38
ALOX5AP P20292 3/20 0.37
FEN1 P39748 3/20 0.37
GAA P10253 1/20 0.36
BTK Q06187 1/20 0.35
JAK2 O60674 1/20 0.33
RORC P51449 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
CYP3A4 P08684 1/20 0.33
DYRK3 O43781 1/20 0.32
ROCK2 O75116 1/20 0.32
RPS6KB1 P23443 1/20 0.32
CLK2 P49760 1/20 0.32
ROCK1 Q13464 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
MKNK2 Q9HBH9 1/20 0.32
CSNK1G1 Q9HCP0 1/20 0.32
STK17A Q9UEE5 1/20 0.32
MTOR P42345 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1359618 0.95 CHEK1 (0.42) CHEK1ALOX5APFEN1GAACYP3A4
SCHEMBL1360132 0.91 CYP3A4 (0.35) CHEK1ALOX5APFEN1GAACYP3A4
SCHEMBL1359812 0.91 KDM1A (0.39) CHEK1GAACYP3A4TDP1L3MBTL1
SCHEMBL1357912 0.91 KDM1A (0.39) CHEK1GAACYP3A4TDP1L3MBTL1
SCHEMBL1357909 0.91 KDM1A (0.39) CHEK1GAACYP3A4TDP1L3MBTL1
SCHEMBL1357846 0.91 HSP90AA1 (0.40) CHEK1ALOX5APFEN1GAACYP3A4
SCHEMBL1359911 0.90 MAPT (0.34) GAACYP3A4
SCHEMBL1359385 0.90 MAPT (0.36) GAACYP3A4
SCHEMBL1359379 0.90 RAB9A (0.39) GAANPC1RAB9AROCK2RPS6KB1
SCHEMBL1358340 0.90 GAA (0.38) GAANPC1RAB9ACYP3A4NPC1L1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067442-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2011-11-29 US claimed
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-04-01 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081658-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS EIF2AK2, POLR2A, HCCS CHEK1 1363/4885ALOX5AP 3018/4885FEN1 2601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.